BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29197031)

  • 21. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
    Paller CJ; Wissing MD; Mendonca J; Sharma A; Kim E; Kim HS; Kortenhorst MS; Gerber S; Rosen M; Shaikh F; Zahurak ML; Rudek MA; Hammers H; Rudin CM; Carducci MA; Kachhap SK
    Cancer Med; 2014 Oct; 3(5):1322-35. PubMed ID: 24989836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas.
    Nair JS; Schwartz GK
    Oncotarget; 2016 Mar; 7(11):12893-903. PubMed ID: 26887042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
    Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process.
    Lordier L; Chang Y; Jalil A; Aurade F; Garçon L; Lécluse Y; Larbret F; Kawashima T; Kitamura T; Larghero J; Debili N; Vainchenker W
    Blood; 2010 Sep; 116(13):2345-55. PubMed ID: 20548097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Cell Biologist's Field Guide to Aurora Kinase Inhibitors.
    de Groot CO; Hsia JE; Anzola JV; Motamedi A; Yoon M; Wong YL; Jenkins D; Lee HJ; Martinez MB; Davis RL; Gahman TC; Desai A; Shiau AK
    Front Oncol; 2015; 5():285. PubMed ID: 26732741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
    Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
    Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny.
    Wiedemuth R; Klink B; Fujiwara M; Schröck E; Tatsuka M; Schackert G; Temme A
    Carcinogenesis; 2016 Oct; 37(10):993-1003. PubMed ID: 27515963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
    Nair JS; de Stanchina E; Schwartz GK
    Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
    Juan G; Bush TL; Ma C; Manoukian R; Chung G; Hawkins JM; Zoog S; Kendall R; Radinsky R; Loberg R; Friberg G; Payton M
    J Transl Med; 2014 Nov; 12():307. PubMed ID: 25367255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypersensitivity to aurora kinase inhibitors in cells resistant against platinum- containing anticancer agents.
    Akiyama M; Izumi H; Wang KY; Yamaguchi T; Kuma A; Kitamura N; Harada Y; Oya R; Yamaguchi K; Iwai Y; Kohno K
    Anticancer Agents Med Chem; 2014; 14(7):1042-50. PubMed ID: 24521151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
    Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.